100% Purple, at this time it will be very likely another 20% of the company will be sold off at current levels, that’s with a 10 % placement and the attachment of options, that’s forty % total including the last CR.
A big question, I doubt the BOD would be transparent on, is the necessary R& D funds needed to progress this IP significantly forward till such time of a partnership or a takeover.
20 million, (R and D spend), seems hugely ‘undermanned’, when you consider what the incumbent first movers are spending.
MC needs to appreciate thru positive sentiment rather than Anteris increasing it via the usual CR, only thing I can see raising that sentiment is a serious offer of interest by a third party.
Until such time …..
Imho.
Ann: DurAVR Maintains Exceptional Results in New Patient Cohort, page-13
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.05 |
Change
0.050(0.26%) |
Mkt cap ! $366.1M | |||
| Open | High | Low | Value | Volume |
| $18.91 | $19.09 | $18.77 | $79.20K | 4.185K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 54 | $18.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.05 | 149 | 1 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.90 |
Change
0.050 ( 1.00 %) |
||||
| Open | High | Low | Volume | ||
| $18.90 | $18.90 | $18.90 | 104 | ||
| Last updated 11.02am 03/06/2024 ? | |||||
| AVR (ASX) Chart |